Precision Management of Late Endocrine Effects in Cancer Survivors

Improved patient outcomes resulting from significant advances in cancer therapies—although a triumph—have also created a new clinical imperative to address long-term sequelae of cancer treatments in survivors. In this interactive forum, you will hear expert perspectives on:

  • Common root causes of late endocrine effects due to cancer treatment in survivors of childhood cancer and the importance of lifelong monitoring for their development
  • Strategies to address barriers to growth hormone deficiency treatment adherence
  • Challenges of mitigating obesity and diabetes mellitus in cancer survivors

*Attendees must be registered for ENDO 2021 to participate.
https://www.endocrine.org/meetings-and-events/endo2021/endo-2021-registration

Agenda

5:30 PM ET Welcome and Program Overview

5:40 PM ET Hypothalamic and Pituitary Axis Dysfunction: A Focus on Growth Hormone Deficiency

6:00 PM ET Thyroid Dysfunction

6:20 PM ET Metabolic: A Focus on Obesity and Diabetes Mellitus

6:45 PM ET Question and Answer Session

7:00 PM ET Adjournment

*Attendees must be registered for ENDO 2021 to participate.
https://www.endocrine.org/meetings-and-events/endo2021/endo-2021-registration 

Faculty

Program Director
Wassim Chemaitilly, MD

Associate Member, St. Jude Faculty
Director, Endocrinology Division
St. Jude Children’s Research Hospital
Memphis, Tennessee

Faculty
Laurie E. Cohen, MD

Faculty
Danielle Novetsky Friedman, MD, MS

Pediatrician
Pediatric Long-term Follow-up Program
Department of Pediatrics
MSK Kids
New York, New York

Faculty
Steven G. Waguespack, MD

Professor
Division of Internal Medicine
Department of Endocrine Neoplasia and Hormonal Disorders
University of Texas MD Anderson Cancer Center
Houston, Texas

SPC Liaison
Andjela T. Drincic, MD

Goal Statement
The goal is to educate healthcare providers in the diagnosis and clinical management of late endocrine effects in pediatric and adult cancer survivors.

Target Audience
The live, virtual symposium is intended for endocrinologists, advanced practice providers, nurses, pharmacists, and other healthcare providers who will attend ENDO 2021 and care for adult and pediatric cancer survivors. 

Learning Objectives
Upon completion of this activity, learners should be able to:

  • Summarize the common root causes of late endocrine effects due to cancer treatment in survivors of childhood cancer and the importance of lifelong monitoring for their development
  • Apply practical strategies to address barriers to growth hormone deficiency treatment adherence
  • Discuss the challenges of obesity and diabetes mellitus in cancer survivors

Accreditation

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by The Endocrine Society and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-21-017-L01-P.

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.